|
| |
BioJournal - Trimark Publications
http://www.bioportfolio.com/cgi-bin/acatalog/TriMark_Publications.html
 |
Veterinary antibacterials - antiseptics that only act against bacteria -
comprise some of the most important pharmaceutical products on the animal
health market. Yet despite a difficult regulatory environment - driven by
concerns over the development of antibacterial resistance in consumers of
livestock products - new products are still being launched. This has
resulted in significant changes in the animal health products market. This
study offers a detailed examination of the shape of the animal health
products market globally over the next several years specific to
antibacterials, analyzing both the livestock and companion animal markets.
|
 |
The medical imaging segments are poised for a major new phase of growth
fueled by the availability of new technology coming out of the computer and
digital information technology segment. Continuous improvements in
technology are resulting in a growing number of new imaging tests that
combine high levels of accuracy with rapid, easy-to-use product formats.
Part of that medical imaging improvement is coming from positron emission
tomography (PET). PET is a scanning technique used in combination with small
amounts of radio-labeled compounds to visualize the anatomy and function of
the brain. The purpose of this TriMark Publications report is to describe
the specific market segment of the diagnostics medical imaging market called
PET scanning. This sector includes all of the generally accepted imaging
activities that are currently used in PET, including equipment for PET,
PET/CT, SPECT and the use of radiopharmaceuticals for imaging. It examines
these clinical measurement devices and their reagents and supplies as used
in hospitals and clinics. It also reviews associated clinical market
segments in which PET scanning has taken a prominent role including cancer
treatment, cardiology and neurology imaging markets. |
 |
Personalized medicine and pharmacogenomics are inextricably linked.
Pharmacogenomics is the use of genetic variations (such as SNPs, gene
expression variability, or other molecular signatures) to understand and
correlate with differential response to pharmaceutical agents (drugs).
Pharmacogenomics can be deployed clinically to stratify patients into
responders and non-responders and this practice is termed personalized
medicine. The purpose of this TriMark Publications report is to describe the
specific market segment of the diagnostics market called personalized
medicine. To frame the context of current approaches, pharmacogenomics seeks
to identify and validate the signature(s) of molecular analytes and these
are converted to assays using the tools of molecular diagnostics. The
deployment of these molecular diagnostics assays on defining and targeting
patient populations is the domain of personalized medicine. This study
includes all of the generally-accepted imaging activities that are currently
used in personalized medicine, including pharmacogenomics, genomics and
theranostics. It examines associated clinical market segments in which
personalized medicine has taken a prominent role including cancer treatment,
cardiology and neurology markets. |
 |
Profound changes are happening in the animal health market. Pet owners
in the United States are demanding more advanced and expensive treatments
for companion animals, driving growth in the companion-animal sector. At the
same time, concerns about livestock health care and feeding are driving
changes in industrial animal husbandry. This TriMark Publications report
offers a broad, yet detailed, overview of the shape of the veterinary health
products market over the next several years. Examining both livestock and
companion-animal markets. The overall market for veterinary therapeutics and
diagnostic products has grown dramatically. This report analyzes the U.S.
veterinary pharmaceuticals and diagnostics markets. The report outlines
market size, market growth, forecasts, and competitive information. Focusing
both on companion (pet) animal markets and agricultural livestock, the
report examines the markets for pharmaceuticals, vaccines, diagnostics, and
feed additives. The study reveals: the size of the markets for
companion-animal products, broken down by type of animal (i.e., cats, dogs,
small animals, etc.); size of the markets for livestock products; how the
Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA)
regulations impact these markets; the identity of the top market players,
along with their market shares and future prospects; how the antibiotic feed
additive controversy is influencing the agricultural market; and key players
in the veterinary pharma and diagnostic markets. |
 |
The area of drug discovery tools is one of the newest and most important
sectors of pharmaceutical research and development. The term drug discovery
tools usually refers to high-content screening (HCS) and analysis and is
composed of those applications that require sufficient levels of sample
throughput, whereby complex cellular events and phenotypes can be studied.
Elements of drug performance like toxicity and specificity can be
established simultaneously using mixed cell types—primary cells, cell lines,
cell subpopulations. HCS seeks to assess the impact of phenotypic and
cellular changes that are brought about by gene modification (such as with
RNA interference (RNAi) approaches) and/or drug (or compound) treatment. The
purpose of this examination by TriMark Publications is to describe the
specific segments of the global drug discovery tools market. Within this
area, the report covers those segments that are highly active in terms of
innovation and growth. Specifically, this study examines the markets for
small lab equipment all the way up to highly automated, large automated
platforms, as well as accessory equipment such as reagents, supplies and
manufacturers’ original equipment manufacturer (OEM) additional equipment. |
 |
Cell therapy technologies and methods have already started to play an
important role in the practice of medicine. Hematopoietic stem cell
transplantation is replacing the old fashioned bone marrow transplants. Cell
therapy is bound to become a part of medical practice. Unlike organs, cells
are a potentially renewable resource for body repair. The goal of this
TriMark Publications report is to review the market for cell therapy
products using screening reagents and instruments for analysis of individual
components in tissue samples, blood, serum or plasma. It defines the dollar
volume of sales, both worldwide and in the U.S., and analyzes the factors
that influence the size and the growth of the market segments. Also examined
are the subsections of each market segment, including the research labs,
hospital labs and commercial laboratories. Additionally, the numbers of
institutions using this type of cell therapy and the factors that influence
purchases are discussed. The study surveys almost all of the companies known
to be marketing, manufacturing or developing instruments and reagents for
the cell therapy market in the U.S. Each company is discussed in extensive
depth with a section on its history, product line, business and marketing
analysis, and a subjective commentary of the company’s market position. |
 |
The area of gene expression reagents is one of the newest and most
important sectors of pharmaceutical and bioscience research and development.
The term gene expression reagents refers to chemicals that are used in gene
expression experiments that are performed to determine whether a particular
gene is expressed--i.e., present--and in some cases at what levels, in a
biological sample. The purpose of this TriMark Publications report is to
describe the specific segments of the global gene expression reagents
market. Within this area, the study covers those segments that are highly
active in terms of innovation and growth. Specifically, this review examines
the markets for gene expression reagents and small lab equipment all the way
up to highly automated platforms. Emphasis is on those companies that are
actively developing and marketing gene expression reagents for genomics
research in the academic sector and the pharmaceutical, bioscience industry.
This study concentrates on the laboratory reagent market segment and the
companion gene expression reagents sector in the U.S. and around the world
that use materials for genetic research. Particular attention is paid to
those areas of the gene expression reagents sector that are showing the
greatest growth or the most innovation. |
 |
Clinical laboratory testing is generally categorized as either of two
general areas-clinical testing and anatomical pathology testing. Clinical
and anatomical pathology procedures are frequently ordered as part of
regular physician office visits and hospital admissions in connection with
the diagnosis and treatment of illnesses. As such, clinical laboratory
analysis is one of the most important sections of medical care. The purpose
of this TriMark Publications report is to describe the specific segments of
the clinical laboratory analysis business. The emphasis in this review is on
those companies that are actively developing and marketing laboratory data
for the clinical setting, including hospitals, independent labs, physician's
offices and miscellaneous clinics. This study concentrates on the clinical
laboratory industry in the U.S. It defines the dollar volume of sales in
each major market and analyzes the factors that influence the size and the
growth of the individual market segments. The study surveys some of the
primary companies known to be marketing clinical laboratory data into the
market. Each company is discussed in depth with a section on the history of
the company, the product line, business and marketing analysis, and a
subjective commentary of the position of the company in its market. |
 |
Clinical laboratory analysis for in vitro diagnostic (IVD) testing is
one of the most important sectors of medical care. By all accounts, it is
very mature, large and diverse--crossing the $33 billion mark in 2006--and
employing over 100,000 laboratory workers, and spawning an industry for
reagents and instruments comprised of thousands of companies worldwide. The
term clinical laboratory analysis usually refers to determining the
concentration or activity of a protein, carbohydrate, lipid, electrolyte,
enzyme or small molecule in easily collected body fluids such as blood,
serum, plasma or urine. However, it is not necessarily limited to these
determinations. The purpose of this TriMark Publications report is to
describe the specific segments of the global clinical laboratory
instrumentation and reagent market. Within this area, the report covers
those segments that are highly active in terms of innovation and growth.
Specifically, this global clinical laboratory markets report examines the
markets for small lab equipment all the way up to highly-automated, large
lab platforms, as well as accessory equipment such as reagents, supplies and
manufacturers' original equipment manufacturer (OEM) additional equipment.
The emphasis in this analysis is on those companies and products that are
actively developing and marketing laboratory analyzer products for the
clinical setting, including hospitals, independent labs, physician's offices
and miscellaneous clinics. This study concentrates on the clinical
laboratory instrumentation industry market segment and the companion
reagents sector in the U.S. and around the world. Particular attention is
paid to those areas of the clinical laboratory instrumentation and reagents
sector that are showing the greatest growth or the most innovation. |
 |
Clinical hematology analyzer analysis is one of the oldest and most
important sectors of clinical laboratory analysis. The hematology instrument
and reagent market is centered around a group of instruments called
hematology analyzers. The term clinical hematology analyzer usually refers
to an automated instrument for determining the presence, number and type of
cellular elements in easily collected body fluids, such as blood. However,
it is not necessarily limited to these determinations. The hematology
analysis always includes determination of non-cellular parameters in blood,
such as hemoglobin and hematocrit. Other closely related areas of clinical
interest are coagulation and flow cytometry. In fact, traditional
specialization barriers, such as microbiology, hematology, blood banking,
immunology and even anatomical pathology are rapidly fading both
operationally and instrumentally. But for the sake of defining the subject
to a reasonable size, the more traditional scope of clinical hematology
analyzer will be the focus of this examination. The purpose of this TriMark
Publications report is to describe the specific segments of the global
clinical hematology analyzer instrumentation and reagent marketplace. The
review covers those segments that are highly active in terms of innovation
and growth. Specifically, this study examines the markets for small-lab, as
well as highly-automated large-lab, platforms and accessory equipment, such
as reagents, supplies and add-on equipment from original equipment
manufacturers. |
 |
A stem cell is an extraordinary type of cell that has the ability to
self-renew for long periods of time and to differentiate into specialized
cells under appropriate physiological or experimental conditions.
Traditionally, stem cells have been classified as either embryonic, adult
(tissue-specific or cord blood) stem cells. Recent understanding of stem
cell biology may provide new approaches for the treatment of a number of
diseases as well as tissue/organ injuries, including cardiovascular disease,
neurological disease, musculoskeletal disease, diabetes and hematopoietic
disorders. |
 |
Since its discovery, the naturally occurring RNA (ribonucleic acid)
interference effect has been acclaimed as the most exciting technical
breakthrough in biological research in the last decade. Some industry
analysts predict that RNA interference (RNAi) may even surpass PCR as a top
technology. RNAi allows scientists to silence the expression or effect of a
gene under study. This is known as gene knockdown. This field has rapidly
emerged as a fast-growing new market. The purpose of this TriMark
Publications report is to review the market for RNAi testing equipment and
supplies. RNAi is a mechanism in molecular biology where the presence of
certain fragments of double-stranded RNA (dsRNA) interferes with the
expression of a particular gene which shares a similar sequence with the
dsRNA. This study defines the dollar volume of sales, both worldwide and in
the U.S., and analyzes the factors that influence market size and growth for
RNAi testing. The main objectives of this study are to: 1) understand the
different sectors of RNAi testing market and to look at a description of the
instruments, reagents and supplies marketed by major companies in each
segment; 2) obtain a complete understanding of the individual RNAi-testing
platforms-from basic principles to clinical applications; 3) discover
feasible market opportunities by identifying high-growth applications in
different analytical diagnostic areas, with a focus on the biggest and
expanding markets; 4) focus on global industry developments and trends
through an in-depth analysis of the major world markets for RNAi measurement
technology, including growth forecasts; and 5) present market figures
related to the current value of RNAi testing, market projections, market
share, key players and sector growth rates. |
 |
The purpose of this report is to analyze and describe the nuclear
cardiology market segments in the U.S. and worldwide. It examines the
measurement devices that are utilized by physicians to diagnose and monitor
heart diseases. This study also discusses key products in nuclear cardiology
and examines the trends that are stimulating this market. It includes a
survey of all major companies actively engaged in marketing, manufacturing
or developing nuclear cardiological instrumentation, with each company
discussed in depth. |
 |
Clinical immunoanalyzer analysis is one of the most important functions of
clinical laboratory analysis. By all accounts, automated immunoassay testing
is the most rapidly developing of the traditional clinical laboratory
sectors. Clinical immunoanalyzer analysis usually refers to determining the
concentration or activity of protein, carbohydrate, lipid, enzyme or small
molecule in easily collected body fluids, such as blood, serum, plasma or
urine. However, it is not necessarily limited to these purposes. The
analysis of virtually any biologically active substance in any place in the
body can generally be defined as clinical immunoassay testing. In fact,
traditional specialization barriers, such as microbiology, hematology, blood
banking, immunology and even anatomical pathology are fading rapidly, both
operationally and instrumentally. This TriMark Publications report deals
with the traditional scope of clinical immunoassay, while looking at the
emerging technology trends in this sector. The purpose of this study is to
describe the specific segments of the global clinical immunoanalyzer
instrumentation market. Within this area, the highly-active segments in
terms of innovation and growth are covered. Specifically, it examines the
markets for small labs and highly-automated large lab platforms, as well as
the market for accessory equipment, such as reagents and supplies. Emphasis
is on those companies and products that are actively developing and
marketing immunoanalyzer products for clinical setting, including hospitals,
independent labs, physician's offices and clinics. |
 |
The purpose of this TriMark Publications report is to describe the
threatening world pandemic caused by avian influenza, also known as bird
flu. This report discusses the origins of the disease, the bird-to-human
infection risks, the catastrophic health crisis avian flu poses, and the
efforts by world governments and international health organizations to
mitigate of the impact the threat to humans. |
 |
The global market for glucose testing products is undergoing a
significant transition driven by the advent of new analytical technologies
and developments in diabetes treatment. Although the glucose testing segment
of the in vitro diagnostics (IVD) industry is mature, certain segments of
the market such as home testing devices for diabetes management will exhibit
strong growth, with some-such as non-invasive testing-representing major new
areas of application for IVD testing. Direct access testing, or
over-the-counter, which allows consumers to order tests themselves without
visiting a doctor, has emerged as a strong force in the glucose-testing
segment. Moreover, an increasing range of test devices is now available to
consumers for use in self-testing. The purpose of this TriMark Publications
report is to describe the specific market segments for blood glucose testing
and diabetes management. This study reviews all of the generally-accepted
clinical analytical methods that are currently in use today for measuring
serum or plasma or whole-blood glucose concentrations. Moreover, it examines
clinical measurement devices, reagents and supplies as utilized in
hospitals, clinics, doctors' offices and at-home care locations. |
 |
Clinical chemistry analysis is one of the most important areas within
clinical laboratory analysis. The term clinical chemistry usually refers to
determining the concentration or activity of a protein, carbohydrate, lipid,
electrolyte, enzyme or small molecule in easily-collected bodily fluids such
as blood, serum, plasma or urine. However, it is not necessarily limited to
these determinations. The analysis of virtually any biologically-active
substance-any place in the body-can loosely be defined as clinical
chemistry. In fact, traditional specialization barriers such as
microbiology, hematology, blood banking, immunology and even anatomical
pathology are rapidly fading, both operationally and instrumentally. But for
the sake of defining the subject to a reasonable size, the more traditional
scope of clinical chemistry will be the subject of this TriMark Publications
study. The purpose of this report is to describe the specific segments of
the global clinical chemistry instrumentation market. Specifically, this
study examines the markets for small lab and highly-automated, large lab
platforms, as well as accessory equipment such as reagents, supplies and
manufacturers' original equipment manufacturer (OEM) additional equipment.
The emphasis is on those companies and products that are actively developing
and marketing chemistry analyzer products for the clinical setting,
including hospitals, independent labs, physician's offices and clinics.
Concentration is on the clinical chemistry instrumentation industry market
segment in the U.S. and around the world. Particular attention is paid to
those areas of the clinical chemistry instrumentation sector that are
showing the greatest growth or the most innovation. |
 |
This TriMark Publications report focuses on the world nutraceuticals and
dietary supplements markets. The product categories examined include
vitamins, minerals, herbal and non-herbal extracts. Additionally, the study
reviews measurement methods and resources utilized in the dietary
supplements industry. Packed with the latest information relating to new
products and industry trends, this analysis not only quantifies but also
qualifies the nutraceuticals market in the areas of research, product
development and investment opportunities. The main objectives of this report
are to: 1) discuss viable market prospects through the identification of
high-growth opportunities in different nutraceuticals and dietary
supplements areas; 2) focus on global dietary supplements industry
development through an in-depth analysis of the major world market,
including forecasts for growth; and 3) examine the use of nutraceuticals and
dietary supplements in pharmaceutical drug development, with examples of its
use in the development and repositioning of therapeutic agents. This study
contains the latest information on the nutraceuticals and dietary
supplements market in the United States. It includes information on the
products that comprise this industry, descriptions, RDA (recommended daily
allowances) where established, common dosages, packaging and quantities. |
 |
Pharmacogenomics, the science of individualizing drug therapy based on
the genetic makeup of individual patients, offers an unusual opportunity for
future market growth. Applying pharmacogenomics would allow doctors to treat
specific segments of the population based on their particular responses to a
drug. The knowledge of the likely effectiveness of a drug in a patient makes
the drug more reliable, and fewer drugs would have to be taken off the
market due to adverse reactions in some, but not all, of the patients to
whom they were administered. Additionally, reducing the occurrence of
adverse effects to a drug effectually reduces the cost of patient care
overall. This TriMark Publications study examines the market for diagnostic
tests based on this science and the clinical measurement methods, the
reagents and supplies being utilized in clinical medicine and the
pharmaceutical industry. This report presents an overview of the latest
information regarding emerging new products and industry trends and will not
only quantify, but also, qualify the pharmacogenomic market segments as an
area of research, product development and investment opportunity. Forecasts
of the pharmacogenomic market and an analysis of products in the worldwide
diagnostics market will provide a basis for understanding the significance
of past developments and the immense possibilities of the future. |
 |
The purpose of this TriMark Publications report is to describe the
sector trends within the point of care testing (POCT) diagnostic market. It
examines those measurement devices and their reagents and supplies that are
utilized in hospitals, clinics, commercial laboratories and research
institutions to detect cells and proteins for the purpose of diagnosis and
monitoring of disease. This study includes all of the generally-accepted
clinical analytical activities that are currently in use today.
Additionally, an analysis of business and technology trends and developing
areas of point of care and HPV testing is provided, along with a review of
the market for point of care testing equipment and supplies in the clinical
and research market segments, using screening reagents and instruments for
analysis of individual components in blood, serum or plasma. This report
defines U.S. and global market dollar sales volume and analyzes factors that
influence the size and growth of market segments. |
 |
A microarray is an arrangement of miniaturized test sites or "spots" on
a surface. Each spot is usually no more than 250 micrometers in diameter and
contains biological molecules--usually DNA or protein--which act as probes
for a test sample applied to the array. The surface may be a glass slide, a
plastic plate with wells or a polymer bead. The microarray format allows
many tests or experiments to be performed simultaneously, in parallel,
leading to the generation of huge amounts of biological information for the
application of only a tiny amount of sample. Microarrays are often also
known as "biochips". The purpose of this TriMark Publications report is to
describe the specific segment of the microarray market aimed at analysis of
proteins and DNA. Protein microarray applications include: 1) expression
profiling; 2) serum-based diagnostics; 3) protein-protein binding assays; 4
drug-target binding; and 5) receptor epitope binding. It examines the market
for DNA and protein array testing equipment and supplies using screening
reagents and instruments for analysis of individual components in blood,
serum or plasma. It defines the dollar volume of sales, both worldwide and
in the U.S., and analyzes the factors that influence the size and the growth
of the market segments. Also examined are the subsections of each market
segment, including the research labs, hospital labs, and commercial
laboratories. Additionally, the numbers of institutions using this type of
testing and the factors that influence purchases are discussed. The report
surveys almost all of the companies known to be marketing, manufacturing or
developing instruments and reagents for the protein array market in the U.S.
Each company is discussed in depth with a section on its history, product
line, business and marketing analysis, and a subjective commentary of the
company's market position. |
 |
Cancer is a group of diseases characterized by uncontrolled growth and
spread of abnormal cells. If the spread is not controlled, it can result in
death. Cancer is caused by both external (chemicals, radiation and viruses)
and internal (hormones, immune conditions and inherited mutations) factors.
Causal factors may act together or in sequence to initiate or promote
carcinogenesis. Ten or more years often pass between exposures or mutations
and detectable cancer. Cancer is treated by surgery, radiation,
chemotherapy, hormones and immunotherapy. The purpose of this TriMark
Publications report is to describe the specific segment of the diagnostic
market aimed at analysis cytology (the examination of cells using optical
microscopy methods) specimens derived from the human female reproductive
tract. It examines the measurement devices and their reagents and supplies
used in hospitals, clinics, commercial laboratories and research
institutions to detect cells and proteins for the diagnosis and monitoring
of disease. The study describes the analytical methods used to separate,
isolate, characterize and quantitate cells, DNA and proteins complex in
biological systems related to the diagnosis and treatment of disease of the
female reproductive tract, such as the cervix and vagina. The emphasis is on
those companies and products that are actively developing and marketing
laboratory instrumentation, reagents and supplies for performing cytology
and related molecular diagnostic tests, such as human papillomavirus (HPV)
and other inflammatory and sexually-transmitted diseases. |
 |
The purpose of this TriMark Publications study is to describe the
specific segment of the pharmaceutical market sector called the Indian
pharmaceutical industry. This sector includes all of the generally-accepted
pharmaceutical manufacturing activities that are currently used today,
including the bulk drug industry, formulations and major therapeutic
segments. It examines these clinical supplies as utilized in hospitals,
clinics and doctor's offices. The principal objectives of this analysis are
to: 1) identify viable technology drivers through a comprehensive look at
various platform technologies for the Indian pharmaceutical industry; 2)
obtain a complete understanding of the Indian pharmaceutical industry
practices from its basic principles to its applications; 3) discover
feasible market opportunities via an identification of high-growth
applications in different areas of the Indian pharmaceutical industry, with
a focus on the biggest and expanding markets for the Indian pharmaceutical
industry; 4) focus on global industry development through an in-depth
analysis of the major world markets for pharmaceutical manufacturing,
including forecasts for growth; and 5) establish the essentials of the
Indian pharmaceutical market including definitions, processes and trends. |
 |
There will be a steady increase in demand for medical imaging services,
along with pressures to improve the quality of healthcare delivered in the
home and to lower its cost. The medical imaging segments are poised for a
major new phase of growth fueled by the availability of new technology
coming out of the computer and digital information technology segment, and
the higher interest of individual older baby boom patients and general
healthcare consumers to monitor health status. Continuous improvements in
technology are resulting in a growing number of new imaging tests that
combine high levels of accuracy with rapid, easy-to-use product formats.
Digital mammography is driving more screening programs. The purpose of this
TriMark Publications report is to describe the specific market segment of
the diagnostics market sector called medical imaging. This sector includes
all of the generally-accepted imaging activities that are currently used
today, including X-ray and radiography, mammography, magnetic resonance
imaging (MRI), ultrasound, gamma camera market, computed tomography (CT)
scans and positron emission tomography (PET) scans. It examines these
clinical measurement devices and their reagents and supplies as used in
hospitals, clinics and doctor's offices. It also includes associated market
segments like picture archiving and communications system (PACS) markets,
cardiology imaging markets, three-dimensional (3D) imaging markets and other
emerging technologies. |
 |
The life science informatics marketplace--known as bioinformatics--is
set to expand as high-tech companies infiltrate this arena and
biopharmaceutical companies incorporate key informatic solutions into their
business strategies. TriMark Publications believes that many of the segments
of bioinformatics described in this report offer an unusual opportunity for
accelerated expansion within the coming years. This study is arranged to
provide an overview of bioinformatics market segments and offer evidence
that these segments are poised for significant future growth. Each segment
is accompanied by analysis and forecasts by product type and application. |
 |
This TriMark Publications report examines the disposable syringe markets
as well as the supplies utilized in clinics and by patients directly in
their homes to diagnose and monitor disease and to administer medications.
This analysis is intended to provide basic market data pertaining to the
U.S. and worldwide market segments. Each market segment is analyzed to
determine size, growth rates, sales projections and factors influencing
growth in the U.S. and internationally. Unit and dollar volume are used to
indicate market sizes. Additionally, this review examines industry
challenges and potential threats to syringe and needle supplies
manufacturers and makes strategic recommendations for boosting market share.
The emphasis is on those companies actively developing and marketing
products to hospitals, physicians and the general public for medically
related uses. The disposable syringe market segments are identified as: 1)
total reusable needle and syringe market; 2) total disposable needle and
syringe market; 3) prefilled syringes; 4) safety syringes; 5) insulin
injector pens; 6) needleless injectors; 7) vaccination injectors; 8) blood
collection needles and syringes; 9) hypodermic needles and syringes market;
10) insulin needles and syringes market; 11) specialty needles and syringes
market; and 12) needleless injector market. |
 |
There will be a steady increase in demand for new diagnostic testing
services in the next five-year period, along with pressures to improve the
quality of healthcare delivered in the clinic and also to lower its costs.
Clinical labs experienced a substantial growth during the last decade. The
emphasis in this TriMark Publications report is on those companies that are
actively developing and marketing high-growth diagnostic testing
technologies in the clinical hospital market. It defines the dollar volume
of sales, both worldwide and in the U.S., of the market and analyzes the
factors that influence the size and growth of market segments. The study
goes on to discuss in detail trends that have developed which have
stimulated this market, and also comments in detail patterns of information
processing in the high-growth diagnostic testing technologies. Moreover,
this exanimation provides an overview of the diagnostic testing market,
including the latest information regarding exciting new products and
industry trends. It will not only quantify but also qualify the market
high-growth segments as an area of research and investment. Forecasts of the
market and analyses of products in the worldwide prescriptions market will
provide a basis for understanding the significance of past developments and
future possibilities within this therapeutic category. |
 |
The purpose of this TriMark Publications report is to describe the
specific market segment of the in vitro diagnostics (IVD) market devoted to
cardiac marker testing. This study examines clinical measurement devices and
their reagents and supplies as used in hospitals, clinics and doctor's
offices. This examination is arranged to provide the reader with an overview
of the outstanding diagnostic test market segments of cardiac care, with
evidence that these segments are poised for high future growth. An overview
of the diagnostic testing cardiac marker market is presented with the latest
information regarding emerging new products and industry trends. It will not
only quantify but also qualify the cardiac marker market segments as an area
of research, product development and investment. Forecasts of the cardiac
marker market and an analysis of products in the worldwide diagnostics
market will provide a basis for understanding the significance of past
developments and future possibilities within this diagnostic category. |
 |
Genomics is transforming the pharmaceutical industry. Companies are
moving from drug discovery and development based on medicinal chemistry to
the design of drugs based on information provided by genomics. Virtually all
of the major pharmaceutical houses have either formed partnerships with
genomics firms that began to emerge in the early 1990s or have created in
house genomics divisions. The aim of this TriMark Publications study is to
provide in depth information on the developing market for genomics products
and services. The report will include detailed market analyses and
discussions of industry trends in order to assess the impact of genomics on
the current and emerging pharmaceutical and diagnostic markets. Forecasts
and trends were developed from interviews with industry sources, as well as
from an assessment of available and emerging technologies. The report
focuses on how researchers are applying new genomic approaches to drug
discovery and development, and on how these technologies can be used most
effectively and in a high throughput capacity. Case studies analyzing
particular applications of genomic technologies to specific disease related
research are provided, and future trends and developments are forecasted.
Information to prepare this study was derived from interviews with product
managers, marketing strategists, research executives and others. These
individuals are employed at leading genomics firms or in pharmaceutical and
biotechnology companies that either contract with these firms or have
developed in house genomics capabilities. |
 |
Cancer testing is one of the most important growth opportunities for the
next three to five years in the diagnostics segment. The National Cancer
Institute estimates that about ten million Americans have or have had some
form of cancer. Overall costs of the disease are $126 billion annually.
Pharmaceutical companies are developing more than 300 new medicines for
cancer, some of which are in development for more than one type of the
disease, for a total of more than 500 ongoing R&D projects. The goal of this
TriMark Publications report is to review the market for tumor marker testing
equipment and supplies using screening reagents and instruments for analysis
of individual components in blood, serum or plasma. It defines the dollar
volume of sales, both worldwide and in the U.S., and analyzes the factors
that influence the size and the growth of the market segments. Also examined
are the subsections of each market segment, including: the physician office
labs, hospital labs and commercial laboratories. Additionally, the numbers
of institutions using this type of testing and the factors that influence
purchases are discussed. The report surveys almost all of the companies
known to be marketing, manufacturing or developing instruments and reagents
for the clinical point-of-care market in the U.S. Each company is discussed
in depth with a section on its history, product line, business and marketing
analysis, and a subjective commentary of the company's market position. |
 |
The technologies that constitute molecular diagnostics-first-generation
amplification, DNA probes, fluorescent in situ hybridization (FISH),
second-generation biochips and microfluidics, next-generation signal
detection, biosensors, and molecular labels-are influencing the discovery of
therapeutic molecules, the screening and diagnosis of patients, and the
optimization of drug therapy. In the past few years, this rapidly evolving
field has seen several fascinating developments. This TriMark Publications
report describes the specific market segment of the in vitro diagnostics
market known as molecular diagnostics and includes all of the generally
accepted clinical analytical activities in use today. It examines the
prevalent clinical-measurement devices, as well as their reagents and
supplies as utilized in hospitals, clinics, large reference laboratories and
doctor's offices. Diagnostic tests marketed primarily as over-the-counter
are generally not included in this report, although there is inevitably some
overlap. The main objectives of this analysis are: 1) identifying viable
technology drivers through a comprehensive look at platform technologies for
molecular diagnostics, including probe-based nucleic acid assays,
microarrays and sequencing; 2) obtaining a complete understanding of the
chief molecular diagnostics tests-i.e., predictive, screening, prognostic,
monitoring, pharmacogenomic and theranostic-from their basic principles to
their applications; 3) discovering feasible market opportunities by
identifying high-growth applications in different clinical diagnostic areas
and by focusing on expanding markets, such as communicable diseases,
cardiology and oncology; and 4) focusing on global industry development
through an in-depth analysis of the major world markets for molecular
diagnostics, including growth forecasts. |
 |
The purpose of this TriMark Publications report is to describe the
specific market segment of the in vitro diagnostics market called point of
care testing (POCT). It examines these clinical measurement devices and
their reagents and supplies as utilized in hospitals, clinics and doctor's
offices. An analysis of analytes that are related to the common chemical
constituents of blood, plasma or serum at the point of care of the patient
is addressed. Moreover, the study defines the dollar volume of sales, both
worldwide and in the U.S., and analyzes the factors that influence the size
and the growth of the market segments. Also examined are the subsections of
each market segment, including the research labs, hospital labs and
commercial laboratories. Additionally, rapid detection of food pathogens and
infectious pathogens (MSRA, herpes simplex, avian flu, West Nile virus and
typhoid) are discussed. The report surveys almost all of the companies known
to be marketing, manufacturing or developing instruments and reagents for
the point of care market in the U.S. Each company is discussed in extensive
depth with a section on its history, product line, business and marketing
analysis, and a subjective commentary of the company's market position. |
 |
This TriMark Publications report describes the specific market segment
of the pharmaceutical market for diabetes and two of its related diseases,
metabolic syndrome and cardiovascular disease. It begins with a textbook
explanation of the biology underlying diabetes, and then it reviews and
evaluates widely accepted pharmaceutical approaches to diabetes that are
currently in use. Finally, market forecasts and an analysis of products in
the worldwide prescriptions market will help the reader understand the
significance of past developments and speculate on future possibilities
about the market of diabetes therapies as an area of research and
investment. The principal objectives of this report are to: 1) identify
viable technology drivers through a comprehensive look at various platform
technologies for diabetes, metabolic syndrome and cardiovascular disease; 2)
provide a complete understanding of the leading diabetes tests that are used
for disease prediction, screening, prognosis and monitoring, encompassing
their basic principles and applications; 3) discover feasible market
opportunities via an identification of high-growth applications in different
therapeutic areas, with a focus on the largest and most rapidly expanding
markets for diabetes, metabolic syndrome and cardiovascular disease; 4)
focus on global industry development through an in-depth analysis of the
major world markets for molecular diagnostics, including forecasts for
growth; and 5) summarize the blood glucose testing market, including
definitions, processes and trends. Market figures regarding the current
value of the diabetes drug market are taken from the most recently available
data of the global pharmaceutical industry. The following categories of
diabetes drugs will be covered herein: 1) rapid-acting insulin; 2)
short-activity insulin; 3) intermediate-acting insulin; 4) long-acting
insulin; 5) ultra-long-acting insulin; 6) insulin mixtures; 7) sulfonylureas;
8) meglitinides; 9) biguanides; 10) thiazolidinediones; and 11) alpha-glucosidase
inhibitors. |
 |
The purpose of this TriMark Publications analysis is to describe the
specific market segments of the over-the-counter (OTC) diagnostic products
and home healthcare markets. It examines the diagnostic measurement devices
and their reagents and supplies that are utilized in clinics and by patients
directly in their homes to diagnose and monitor disease. This study also
includes a review of home healthcare kits and devices that measure
health-related conditions. Focus is on market dynamics and current market
drivers of the OTC and home self-testing diagnostics market. This report
also looks at the industry challenges and potential threats, and it makes
strategic recommendations for boosting market share. The analysis covers
healthcare-related devices that are designed for the home market in order to
allow consumers to assess their health status through self-testing. In
addition, this review examines some biowarfare detection systems. The
emphasis in this report is on those companies and products that are actively
developing and marketing diagnostic reagents and supplies in market segments
that are targeted for direct sale to the public. It is believed that this
market segment has the potential for growth rates above 15% per year over
the next five years in some of the less well-explored and well-developed
areas. |
http://www.bioportfolio.com/cgi-bin/acatalog/sitemap.html
|
